Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Rallybio's profit margin for the twelve months ending Sep 30, 2026 was 6177.4%. For fiscal 2025 it was -1046.4%, against -9084.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1046.4% | +8037.7 |
| FY2024 | Dec 31, 2024 | -9084.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -3904.7% | +547.6 |
| Q4 FY2025 | Dec 31, 2025 | -2636.0% | +26427.1 |
| Q3 FY2025 | Sep 30, 2025 | 7554.7% | +11389.5 |
| Q2 FY2025 | Jun 30, 2025 | -4576.9% | +853.2 |
| Q1 FY2025 | Mar 31, 2025 | -4452.4% | – |
| Q4 FY2024 | Dec 31, 2024 | -29063.2% | – |
| Q3 FY2024 | Sep 30, 2024 | -3834.8% | – |
| Q2 FY2024 | Jun 30, 2024 | -5430.1% | – |
See a number that looks wrong?